MedTrace Logo

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

NCT07240922 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-05-15

No results posted yet for this study

Summary

This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine response and vaccine failure, and biological factors that could explain variation in influenza vaccine effectiveness.

Conditions

Interventions

BIOLOGICAL

Live attenuated influenza vaccine

0.2mL nasal spray live attenuated influenza vaccine (FluMist, AstraZeneca)

BIOLOGICAL

Placebo nasal spray

0.2mL saline placebo nasal spray

BIOLOGICAL

recombinant hemagglutinin influenza vaccine

0.5mL recombinant hemagglutinin influenza vaccine (Flublok, Sanofi)

BIOLOGICAL

Placebo injection

0.5mL saline placebo injection

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Benjamin J Cowling, PhD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2030-10-01
Completion
2030-10-01
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07240922 on ClinicalTrials.gov